FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of January 2023
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Acquisition
of Neogene Therapeutics completed
16 January 2023
07:00 GMT
Acquisition of Neogene Therapeutics completed
AstraZeneca has completed
the acquisition of Neogene
Therapeutics Inc. (Neogene), a global clinical-stage
biotechnology company pioneering the discovery, development and
manufacturing of next-generation T-cell receptor therapies
(TCR-Ts).
Neogene
will operate as a wholly owned subsidiary of AstraZeneca, with
operations in Amsterdam, the Netherlands and California,
US.
Financial considerations
AstraZeneca
has acquired all outstanding equity of Neogene in exchange for an
initial payment of $200m. Under the terms of the agreement,
AstraZeneca will pay up to $120m in additional contingent
milestone-based and non-contingent consideration.
Notes
Neogene
Therapeutics
Neogene
Therapeutics, Inc. is a global biotechnology company focused on
discovering, developing and manufacturing next-generation,
transformative TCR therapies targeting neoantigens in solid
cancers. Neogene is advancing a pipeline of fully individualized
TCR therapies as well as TCR therapies targeting shared
neoantigens, including mutated KRAS (mKRAS) and mutated TP53
(mTP53).
Neogene
was founded by Carsten Linnemann, PhD, Chief Executive Officer of
Neogene, and Ton Schumacher, PhD, Principal Investigator at the
Netherlands Cancer Institute, Oncode Institute in partnership with
Two River, and cell therapy industry veteran Arie Belldegrun, MD,
founder of Kite Pharma, Inc. and Co-Founder and Executive Chairman
of Allogene Therapeutics, Inc. as well as key investments from Vida
Ventures, TPG, EcoR1 Capital, Jeito Capital, Syncona, Polaris
Partners and Pontifax.
Neogene has EU headquarters in
Amsterdam and U.S. headquarters in Santa Monica. Its team of over
120 employees has deep gene and cell therapy expertise and a shared
mission to bring next-generation transformative TCR therapies to
patients with solid cancers worldwide. Please
visit www.neogene.com and
follow Neogene on LinkedIn.
AstraZeneca in oncology cell
therapy
AstraZeneca
is building a cell therapy portfolio that aims to empower and equip
the immune system's T cells to more effectively fight cancer. The
Company is building on the work already done in blood cancers where
chimeric antigen receptor T-cell (CAR-T) therapies, a type of
living medicine created by isolating and modifying a patient's T
cells to target their specific tumour, are being used to treat some
haematological malignancies. Their research teams are exploring new
ways to target and arm CAR-Ts to increase their effectiveness in
solid tumours by overcoming the immune-suppressive tumour
microenvironment. Looking to the future, AstraZeneca is working to
engineer next-generation cell therapies, where physicians could
potentially select from a library of off-the-shelf patient-ready
therapies already developed from the cells of healthy
donors.
Ultimately,
by utilising innovative strategies to improve the precision and
effectiveness of cell therapies, the Company's goal is to deliver
new medicines to help transform the lives of patients living with a
range of cancers.
AstraZeneca in oncology
AstraZeneca
is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand
cancer and all its complexities to discover, develop and deliver
life-changing medicines to patients.
The
Company's focus is on some of the most challenging cancers. It is
through persistent innovation that AstraZeneca has built one of the
most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca
has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN)
is a global, science-led biopharmaceutical company that focuses on
the discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
16 January 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Feb 2023 bis Mär 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mär 2022 bis Mär 2023
